Organon & Co. Files 8-K on Financials

Ticker: OGN · Form: 8-K · Filed: Feb 13, 2025 · CIK: 1821825

Organon & CO. 8-K Filing Summary
FieldDetail
CompanyOrganon & CO. (OGN)
Form Type8-K
Filed DateFeb 13, 2025
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: financial-results, sec-filing, regulation-fd

TL;DR

Organon & Co. dropped an 8-K detailing financial results and Reg FD disclosures.

AI Summary

Organon & Co. filed an 8-K on February 13, 2025, reporting on its Results of Operations and Financial Condition, along with Regulation FD disclosures and financial statements. The filing provides updates on the company's financial performance and related disclosures.

Why It Matters

This filing provides crucial updates on Organon & Co.'s financial health and operational performance, which can impact investor decisions and market perception.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not appear to contain any immediate, significant negative news.

Key Players & Entities

FAQ

What specific financial results are being reported by Organon & Co. in this 8-K?

The filing indicates it pertains to 'Results of Operations and Financial Condition' but does not detail specific figures within the provided text.

When was the earliest event reported in this Form 8-K?

The earliest event reported was on February 13, 2025.

What is the primary business address of Organon & Co. as listed in the filing?

The primary business address is 30 Hudson Street, Floor 33, Jersey City, NJ 07302.

Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?

This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What other items are included in this 8-K filing besides financial condition?

The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.

Filing Stats: 751 words · 3 min read · ~3 pages · Grade level 10.9 · Accepted 2025-02-13 08:01:36

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On February 13, 2025, Organon & Co. (the " Company ") issued a press release (the " Earnings Release ") regarding its results for the quarter and full year ended December 31, 2024. The Earnings Release is included as Exhibit 99.1 to this report. The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is considered to be "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to liability under that Section. The information in this Current Report shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended (the " Securities Act ") or the Exchange Act, except as shall be expressly set forth by specific reference in such filing or document. The release contains forward-looking statements regarding the Company and includes a cautionary statement identifying important factors that could cause actual results to differ materially from those anticipated.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. In connection with the conference call announced in the Earnings Release, on February 13, 2025, the Company made available the Company Information Presentation relating to its financial results for the quarter and full year ended December 31, 2024. The Company Information Presentation may be accessed within the investor relations section of the Company's website, https://www.organon.com. A copy of the Company Information Presentation is attached hereto as Exhibit 99.2 and is incorporated herein by reference. The information in this Item 7.01, including Exhibit 99.2 attached hereto, is considered to be "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to liability under that Section. The information in this Current Report shall not be incorporated by reference into any filing or other document pursuant to the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing or document. The Company Information Presentation contains forward-looking statements regarding the Company and includes a cautionary statement identifying important factors that could cause actual results to differ materially from those anticipated.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated February 13, 2025, relating to results of operations and financial condition. 99.2 Company Information Presentation. 104 The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Organon & Co. By: /s/ Matthew Walsh Name: Matthew Walsh Title: Chief Financial Officer Dated: February 13, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing